Wuxi Xdc Cayman, Inc. · HKEX:2268
Wuxi Xdc Cayman — H1 2026 Earnings Presentation
34 slides from Wuxi Xdc Cayman's earnings presentation, Aug 24, 2026
Slide 1: Inside Information: 2026 Interim Results Presentation
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia
Slide 2: Announcement notice and forward-looking statements
Further, to ensure that all shareholders and potential investors of the Company have equal and timely access to such information, the Company has included in this announcement the full copy of the Presentation. Shareholders and potential investors of the Company are reminded that the Presentation ma
Slide 3: WuXi XDC 2026 Interim Results
Stock Code: 2268.HK WuXi XDC 2026 Interim Results 25 August, 2026 | Hong Kong 1
Slide 4: Disclaimer
Disclaimer Forward-Looking Statements This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although
Slide 5: Contents
WuXi XDC: Pure-play and the Best CDMO Winner for Bioconjugates Three-Year Consecutive Winner of the Contents “Best CDMO” At World ADC Awards in 2023, 2024, 2025 and 1 2026 Interim Results Highlights Winner of the “Best CRO” At World ADC Awards in 2025 2 Business and Operation 3 Financial Results 4 O
Slide 6: 2026 Interim Results Highlights
01 2026 Interim Results Highlights
Slide 7: Robust Business Growth and Outstanding Financial Results
Robust Business Growth and Outstanding Financial Results Projects(1) Key Financial Results and Backlog (RMB Change in % IFRS mm) AER(3) CER(3) 51 Newly signed iCMC projects Revenue 3,701.4 +37.0% +41.5% Gross Profit 1,371.3 +40.6% 2 New PPQ projects signed Gross Profit Margin 37.0% +0.9ppts Adjusted
Slide 8: Key Achievements and Milestones
Key Achievements and Milestones - Serving 810+ customers worldwide, 160+ global IND submissions by 2026 1H cumulatively - “R” validation in WuXiTecan-2TM out-licensing: Innovation & Earendil Labs one more out-licensing deal signed Execution and with a European biotech company Licensing deal value $8
Slide 9: Business and Operation
b 02 Business and Operation SS —E
Slide 10: Our Business Model Continues to Win Customers and Projects Globally
Our Business Model Continues to Win Customers and Projects Globally Number of Projects Through “Enable – Follow – Win” Strategy “R” "Research”: Enable discovery to PCC 1325 Discovery(1) / 1039 (3) 77 projects advanced from discovery to iCMC stage (1) 166 Preclinical / 124 (3) "Development": Faster r
Slide 11: WuXi XDC Standalone Projects Funnel
WuXi XDC Standalone Projects Funnel Number of Projects Through “Enable – Follow – Win” Strategy "Research”: Enable discovery to PCC “R” 1246 Discovery(1) / 1039 (3) 75 projects advanced from discovery to iCMC stage (1) 145 Preclinical / 124 (3) "Development": Faster route to IND Seamless transition
Slide 12: 51 Newly Signed Projects: Powering Innovation-Driven Growth in CRDMO
51 Newly Signed Projects: Powering Innovation-Driven Growth in CRDMO Sustained momentum Innovative Signed Project Highlights in iCMC(1) projects signing 70 ~30% ~22% 53 51 ADCs w. novel targets/payload- XDCs 75%+(3) linkers(2) 37 emerging novel targets/payload- linkers and ~16% ~8% modalities Bi-spe
Slide 13: Commercial and PPQ Pipeline: A Solid Foundation for Commercial Success
Commercial and PPQ Pipeline: A Solid Foundation for Commercial Success Commercial Projects Profile PPQ Projects Profile 2 ~50% 9 14 Commercial Overseas MNC/ Differentiated Projects Projects Biopharma Targets/MoAs Customers ➢ Commercial supply in China ➢ The 21 PPQ projects include both commercially
Slide 14: Expanding Customer Base and Deepening Global Pharma Partnerships
Expanding Customer Base and Deepening Global Pharma Partnerships Drive Strong Growth Momentum Increasing Customer Base Growing Multinational Pharma Presence Cumulative +144 643 +171 814 15 ~34% +154 499 out of 20 345 Global pharma customers from Revenue contributed by “Top 20 Pharmaceutical “Top 20
Slide 15: Commitment to Cutting-Edge Technologies, Empowering Next-gen ADCs
Commitment to Cutting-Edge Technologies, Empowering Next-gen ADCs and Novel Bioconjugates We continue to expand and advance our proprietary technologies WuXiDARxTM WuXi Payload-LinkerTM No antibody engineering , and no enzyme needed Offering variety of PLs with favorable hydrophilicity for next-gen
Slide 16: 22,000+ Bioconjugate Molecules Created
22,000+ Bioconjugate Molecules Created — Driven by Our Technology and Expertise .. Bioconjugation PD Experience(2) Diversified Projects .. For Diversified Modalities Antibody Peptide ADC Projects Conjugates (APC) 22,000+ Bioconjugate molecules Antibody Oligos Conjugation (AOC) 967 286 discovery proj
Slide 17: Empower ADC/XDC Innovation through Differentiated Bioconjugate Molecules
Empower ADC/XDC Innovation through Differentiated and Abundant Bioconjugate Molecules Research Engine: 3,100+ ADC/XDC Molecules Explored in 2026 1H ~1,600 ~1,000 ADC Molecules XDC Molecules 600+ 52% 32% ~300 ~260 (30%) (~26%) 2,300+ ~1,350 AOC APC 16% ~500 Intermediate ~250 Molecules (24%) Regular A
Slide 18: Our Global R&D and Manufacturing Network
Our Global R&D and Manufacturing Network Wuxi Shanghai Suzhou(BioDlink) Singapore • mAb intermediate Global R&D Center mAb, DS, DP manufacturing • mAb intermediate • Payload-linker • Drug substance • Drug substance • Drug product • Drug product Jiangyin (under construction) Hefei “All-in-one manufac
Slide 19: Wuxi Site: All-in-One Manufacturing for Clinical and Commercial Projects
Wuxi Site: All-in-One Manufacturing for Clinical and Commercial Projects Wuxi Site Overview • High utilization on current 7 production lines (XPLM1 L1, BCM1, BCM2 L1, BCM2 L2, DP1, DP2 and DP3) • New XPLM1 L2 is under construction, target to GMP release by late 2026/early 2027 • New additional DP li
Slide 20: Singapore Site: Cornerstone for Commercial Manufacturing
Singapore Site: Cornerstone for Commercial Manufacturing GMP release in August 2026 A Modular Fabrication MFG Site GMP release schedule • GMP release of mAb/BCM3 (mAb, DS) and DP4 (DP) in August 2026 • GMP release of BCM4 by late 2026 Better Service through Innovation Service Scopes • World-class ma
Slide 21: Jiangyin Site: New Capacity for Large Scale Payload-linker Manufacturing
Jiangyin Site: New Capacity for Large Scale Payload-linker Manufacturing Large-scale Payload-linker Commercial Manufacturing Conceptual rendering ➢ High potent (OEB 5) and non-HP areas ➢ R&D for novel payload modalities ➢ XPLM2 with larger batch size, with total capacity up to 3-5 tons/yr ➢ 5x the v
Slide 22: Payload-Linker Business Emerging as a New Growth Engine
Payload-Linker Business Emerging as a New Growth Engine, Strengthening One-Stop Differentiation Payload-linker Capabilities ➢ Our in-house payload-linker manufacturing network further strengthens our differentiated “one-stop” strategy, providing seamless support across the entire value chain. ~50% ➢
Slide 23: BioDlink Integration
BioDlink Integration Following the acquisition, WuXi XDC holds a majority controlling stake of over 60% in BioDlink, enabling full consolidation and the integrated expansion of the service offering. Synergy Values Strategic Alliances & Partnerships — Service Upgrade & Differentiation — Forming syner
Slide 24: Financial Results
; 03 Financial Results — ——S
Slide 25: Consolidated Group Key Financial Performance
Consolidated Group Key Financial Performance Revenue Gross Profit Adjusted Net Profit Attributable to Owners of the Company(2) (RMB mm) (RMB mm) (RMB mm) 36.1% 37.0% 27.7% 27.8% AER(1) YoY: 37.0% CER(1)YoY: 41.5% YoY: 40.6% YoY: 37.4% 3,701 1,371 1,027 2,701 975 748 2025 1H 2026 1H 2025 1H 2026 1H 2
Slide 26: WuXi XDC Standalone Key Financial Performance
WuXi XDC Standalone Key Financial Performance Revenue Gross Profit Adjusted Net Profit Attributable to Owners of the Company(2) (RMB mm) (RMB mm) (RMB mm) 36.1% 37.6% 27.7% 28.9% AER(1) YoY: 31.7% CER(1) YoY: 36.2% YoY: 37.1% YoY: 37.5% 3,556 1,337 1,028 2,701 975 748 2025 1H 2026 1H 2025 1H 2026 1H
Slide 27: Strong Revenue Growth Underpinned by Diversified Project Status and Region
Strong Revenue Growth Underpinned by Diversified Project Status and Region Revenue Breakdown by Project Status Both pre-IND and post-IND Revenue Increased 2024 2025 2026 1H Significantly Total Revenue 4,052.3 5,944.2 3,701.4 (RMB mm) • Pre-IND Revenue: Rapid growth highlights our strong “R” and “D”
Slide 28: Standalone Margins Continued to Improve, with BioDlink Integration Affecting Group Margins
WuXi XDC Standalone Margins Continued to Improve, with BioDlink Integration Temporarily Affecting Group Margins Gross Profit Margin - Group Gross Profit Margin – WuXi XDC Standalone +1.0% +1.6% +0.9% +1.5% 36.0% 36.1% 37.0% 36.0% 36.1% 37.6% 2025 2025 1H 2026 1H 2025 2025 1H 2026 1H Margin of Adjust
Slide 29: Solid Growth of Backlog in 2026 1H
Solid Growth of Backlog in 2026 1H Number of Projects Through “Enable – Follow – Win” Strategy Solid Backlog Growth USD mm 62.2% YoY (total backlog) “R” 2,156 1325 Discovery(1) / 1039 (3) 50.3% YoY 50.4% YoY 1,489 (service backlog) 1,998 1,329 166 Preclinical / 124 (3) 991 105 Phase I / 86 (3) 2024
Slide 30: List of Facilities and Capex Plan
List of Facilities and Capex Plan WuXi XDC Standalone Facilities BioDlink(1) Operational Facilities 2024 2025 2026 2027 2024 2025 2026 2027 NO Facility NO Facility 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H 1 BCM1(DS) GPM release in 2019 1 DS01(mAb)(2) GPM release in 2018 2 BCM2 L1 (mAb/DS) GPM
Slide 31: Outlook and Summary
; 04 Outlook and Summary ————
Slide 32: A Unified Vision and Strategic Blueprint for Commercial Success
A Unified Vision and Strategic Blueprint for Commercial Success Commercialization Strategy - a systematic growth engine built around diversified MFG capabilities, rich funnel, and globalization Growth Target ADC/BsADC, AOC, by 2030 Modalities ADC ADC + APC, DpADC 20% Wuxi, Singapore, of revenue from
Slide 33: Growth Strategy for 2025-2030: R, D, M Firing in All Cylinders
Growth Strategy for 2025-2030: R, D, M Firing in All Cylinders Co. CAGR 30-35%(1) 2025 2030 “All-in-One” Elevating Our Vision for Further Enhanced Industry average ~25.6%(2) Industry Leadership R Frontier Molecule D Acceleration to FIH M Commercial MFG • Sustained commitment to core • Seamless integ
Slide 34: Key Summary
Key Summary Industry growth momentum remained strong BioDlink post-acquisition integration synergies and value capture through operational optimization and capacity scaling New modality opportunities: such as BsADC, DpADC, AOC, APC and other XDCs Accelerated payload-linker growth and potential techn